MedTrace Logo

GEMINI-NSCLC: NSCLC Biomarker Study

NCT05236114 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-02-05

No results posted yet for this study

Summary

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.

Conditions

Interventions

OTHER

Observation

No intervention

Sponsors & Collaborators

Principal Investigators

  • Virginia Rhodes, MD · Tempus AI, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2029-06-30
Completion
2029-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05236114 on ClinicalTrials.gov